A Phase 3 interventional study of Maridebart Cafraglutide and Placebo in Atherosclerotic Cardiovascular Disease, Overweight and Obesity, sponsored by Amgen. Active, not recruiting at 783 sites in 36 countries. Open to participants aged 45 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 468 studies in Atherosclerosis with a site in United States — 47 open to participants now, 75 under way, 17 of them phase 3. Atherosclerosis · United States.
Among the 468 studies in Atherosclerosis with a site in United States, this one is the 13th largest by planned enrollment of the 328 interventional ones that give a count, is one of 18 that started in 2025, is one of 61 in phase 3, reaches primary completion later than 51 of the 70 other live ones, and was the 444th registered.
1,519 studies on the registry are indexed under Atherosclerosis; 225 are open to participants now.
Browse Atherosclerosis studies →47 of the 468 studies in Atherosclerosis with a site in United States are open now. Recruiting first, the newest first:
University of Colorado, Denver · Sites in United States
Ages 55+
Verve Therapeutics, Inc. · Sites in United States
Ages 18–70
St. Jude Children's Research Hospital · Sites in United States
Ages 18+
Eli Lilly and Company · Sites in United States, Argentina, Japan and 1 more country
Ages 18+
Washington University School of Medicine · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 161 Atherosclerosis studies recruiting now, 84 (52%) set no upper age limit and 33 (20%) stop at 75 or younger; 16 take children under 18; 33 take healthy volunteers.
This study: 45 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
468 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 46 · Phase 2 84 · Phase 3 74 · Phase 4 45
First in 1973; this study’s year is marked. 18 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 12,800 is above the median of 100 across 880 interventional studies indexed under Atherosclerosis.
Median enrollment 119 across the 328 interventional studies, 170 across the 137 observational. Of the 366 that completed or were terminated, 134 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
141 of 468 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Amgen has 5 studies filed under Atherosclerosis — fewer than ten, so there is no comparison to draw.
23 of the studies in Atherosclerosis with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05202509Phase 3NewAmsterdam PharmaCardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease | 2026-11 |
| NCT07000123Phase 3AstraZenecaA Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event | 2027-01-11 |
| NCT05132439Phase 3VA Office of Research and DevelopmentMetfOrmin BenefIts Lower Extremities With Intermittent Claudication | 2027-02-28 |
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
| NCT07121010University of PittsburghHow Animal and Plant Protein Shakes Change the Body's Nutrient and Health Responses | 2026-12 |
Add all 23 to your calendar (.ics) → With an account.
Among the 468 studies in Atherosclerosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
History of Atherosclerotic Cardiovascular Disease (ASCVD) with a documented history of at least one of the following:
Exclusion Criteria
For participants with T2DM (including those without a prior history of T2DM but with a ≥ 6.5% during screening):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive maridebart cafraglutide subcutaneously (SC).
Drug: Maridebart Cafraglutide
Participants will receive placebo SC.
Drug: Placebo
Maridebart cafraglutide will be administered SC.
Also known as: AMG 133, MariTide
Placebo will be administered SC.
Time to First Occurrence of a Composite Endpoint Consisting of: CV Death, Myocardial Infarction (MI), or Ischemic Stroke (3-point Major Adverse Cardiac Events [3-P MACE])
Time frame: Up to approximately 35 months
Time to First Occurrence of a Composite Endpoint Consisting of: All-cause Death, MI, Ischemic Stroke, Coronary Revascularization, or Heart Failure (HF) Event (5-point MACE)
Time frame: Up to approximately 35 months
Time to First Occurrence of a Composite Endpoint Consisting of: CV Death, MI, Ischemic Stroke, or HF Event
Time frame: Up to approximately 35 months
Time to First Occurrence of a Composite Endpoint Consisting of: CV Death, MI, Ischemic Stroke or Coronary Revascularization
Time frame: Up to approximately 35 months
Time to First MI
Time frame: Up to approximately 35 months
Time to First Ischemic Stroke
Time frame: Up to approximately 35 months
Time to CV Death
Time frame: Up to approximately 35 months
Time to All-cause Death
Time frame: Up to approximately 35 months
Time to First Coronary Revascularization
Time frame: Up to approximately 35 months
Time to First HF Event
Time frame: Up to approximately 35 months
Time to First HF Event or CV Death
Time frame: Up to approximately 35 months
Time to First Unstable Angina Requiring Hospitalization
Time frame: Up to approximately 35 months
Time to First Occurrence of MI or CV Death
Time frame: Up to approximately 35 months
Time to First Occurrence of MI, Ischemic Stroke or All-cause Death
Time frame: Up to approximately 35 months
Total Major Ischemic Events (Time to First and Recurrent MI or Ischemic Stroke)
Time frame: Up to approximately 35 months
Total All-cause Hospitalizations (Time to First and Recurrent Event)
Time frame: Up to approximately 35 months
Time to Onset of Type 2 Diabetes Mellitus (T2DM) in Participants with Prediabetes at Baseline
Time frame: Up to approximately 35 months
Time to Onset of T2DM in Participants without T2DM at Baseline
Time frame: Up to approximately 35 months
Change from Baseline in Systolic Blood Pressure (SBP) at Week 72
Time frame: Baseline and Week 72
Change from Baseline in Diastolic Blood Pressure (DBP) at Week 72
Time frame: Baseline and Week 72
Change from Baseline in Body Mass Index (BMI) at Week 72
Time frame: Baseline and Week 72
Change from Baseline in Waist Circumference at Week 72
Time frame: Baseline and Week 72
Change from Baseline in Urine Albumin-to-creatinine Ratio (uACR) at Week 72
Time frame: Baseline and Week 72
Change from Baseline in Hemoglobin A1c (HbA1c) at Week 72
Time frame: Baseline and Week 72
Change from Baseline in Fasting Plasma Glucose at Week 72
Time frame: Baseline and Week 72
Percent Change from Baseline in High-sensitivity C-reactive protein (hs-CRP) at Week 72
Time frame: Baseline and Week 72
Percent Change from Baseline in Body Weight at Week 72
Time frame: Baseline and Week 72
Percent Change from Baseline in Total Cholesterol at Week 72
Time frame: Baseline and Week 72
Percent Change from Baseline in High-density Lipoprotein Cholesterol (HDL-C) at Week 72
Time frame: Baseline and Week 72
Percent Change from Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 72
Time frame: Baseline and Week 72
Percent Change from Baseline in Triglycerides (TG) at Week 72
Time frame: Baseline and Week 72
Number of Participants at Week 72 with HbA1c < 6.5% (48 mmol/mol) in Participants with T2DM at Baseline
Time frame: Baseline and Week 72
Number of Participants at Week 72 with HbA1c < 6.0% (42 mmol/mol) in Participants with T2DM at Baseline
Time frame: Baseline and Week 72
Number of Participants at Week 72 with HbA1c < 5.7% (39 mmol/mol) in Participants with T2DM at Baseline
Time frame: Baseline and Week 72
Number of Participants at Week 72 with HbA1c < 6.5% (48 mmol/mol) in Participants Without T2DM at Baseline
Time frame: Baseline and Week 72
Number of Participants at Week 72 with HbA1c < 6.0% (42 mmol/mol) in Participants Without T2DM at Baseline
Time frame: Baseline and Week 72
Number of Participants at Week 72 with HbA1c < 5.7% (39 mmol/mol) in Participants Without T2DM at Baseline
Time frame: Baseline and Week 72
Number of Participants at Week 72 with HbA1c < 5.7% (39 mmol/mol) in Participants with HbA1c ≥ 5.7% and < 6.5% at Baseline
Time frame: Baseline and Week 72
Change from Baseline in Short Form 36 Health Survey Acute Version 2 (SF-36 v2) Physical Function Domain Score at Week 48
Time frame: Baseline and Week 48
Time to First Event of a Composite Nephropathy Endpoint
Composite endpoint consists of onset of persistent macroalbuminuria, persistent ≥ 40% reduction in estimated glomerular filtration rate (eGFR), onset of persistent eGFR \< 15 mL/min/1.73 m\^2, initiation of chronic renal replacement therapy (dialysis or transplantation), CV or renal death.
Time frame: Up to approximately 35 months
Change in eGFR (total slope) for the period from baseline to the final follow up visit
Time frame: Baseline up to approximately 35 months
Change in eGFR (chronic slope) for the period from 4 months to the final follow-up visit
Time frame: From 4 months up to approximately 35 months
Time to First Occurrence of a Major Adverse Limb Event (MALE) Defined as Acute Limb Ischemia, Urgent Peripheral Revascularization, Major Amputation Due to a Vascular Etiology or Chronic Limb-threatening Ischemia Requiring Revascularization
Time frame: Up to approximately 35 months
Total Arterial (Coronary, Cerebrovascular, and Peripheral) Revascularization Procedures (Time to First and Recurrent Event)
Time frame: Up to approximately 35 months
Time to First Occurrence of a Composite Endpoint Consisting of: CV Death, MI, Ischemic Stroke, MALE, or Arterial Revascularization
Time frame: Up to approximately 35 months
Time to First Occurrence of a Composite Endpoint Consisting of: CV Death, MI, Ischemic Stroke, or Acute Limb Ischemia
Time frame: Up to approximately 35 months
Time to First Occurrence of a Composite Endpoint Consisting of CV Death, MI, Ischemic Stroke, Acute Limb Ischemia, or Urgent Arterial Revascularization Procedure (Coronary, Cerebrovascular or Peripheral)
Time frame: Up to approximately 35 months
Number of Participants with Treatment-emergent Adverse Events
Time frame: Up to approximately 35 months
Number of Participants with Serious Adverse Events
Time frame: Up to approximately 35 months
Plasma Concentration of Maridebart Cafraglutide at Week 72
Time frame: Week 72
Showing the first 100 of 783 sites across 36 countries. Choose a country and city above to see the rest.
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this trial will be considered beginning 18 months after the trial has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe, or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this trial.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen trial/trials in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Data sharing details ↗ · www.amgen.com
Started Jul 2025 (actual). Primary completion is estimated for Jun 2028, 35 months after the start.
Of 36 industry-sponsored phase 3 interventional studies under Atherosclerosis, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 51. This study's planned 35 months is close to that.
Counting every sponsor, half of 53 studies reached it within 35 months; a quarter within 21 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Maridebart cafraglutide